Development and validation of a UPLC-MS/MS method for the quantification of asciminib and its pharmacokinetic interaction and metabolic stability with shikonin
Abstract Asciminib has been approved for use in patients with chronic myeloid leukemia (CML) in the chronic phase. Shikonin has multiple pharmacological effects and is a mixed inhibitor of CYP450 enzymes. In clinical practice, the combination of asciminib and shikonin may lead to drug interactions....
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
BMC
2025-11-01
|
| মালা: | BMC Pharmacology and Toxicology |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://doi.org/10.1186/s40360-025-01049-0 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|